CClinicalTrials.gg
CompletedNCT03189056Updated Mar 29, 2018

Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation

An observational study in Chagas' Disease (Chronic) With Other Organ Involvement, sponsored by Institut de Recherche pour le Developpement. Completed at 1 site in Bolivia. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Institut de Recherche pour le Developpement · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
152
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Chagas disease is one of the most neglected vector-borne infectious disease worldwide. The first decades following the discovery of the pathology drove an international research enthusiasm, mainly concentrated on understanding the typical cardiac and digestive forms. Recently, research have been focused on vector control, which has been a huge success, at the price of neglecting the patients who already presented fixed and severe organic lesions due the chronic phase of the illness.

This study focus on a rarely studied aspect of this pathology: the involvement of the lower urinary tract and it's symptomatology in adults suffering from Chagas chronic disease.

Various studies have assessed the involvement of the lower urinary tract in chronic Chagas disease, the vast majority of them being on the animal model or very ancient human studies mainly on cadaveric specimen, the first of them being the primary description of Koeberle in 1963.

Human symptomatology deriving from bladder, ureteral and urethral chronic chagasic lesions are yet widely unknown, and only a few Brazilian and Mexican studies have intended to describe the clinical and urodynamic presentation of these patients.

The aim of this study is to assess the prevalence of urinary disorders in chronic chagasic patients and to describe their symptoms, through a complete clinical, ultrasonographic and urodynamic description.

Read the detailed description

Epidemiologic observationnal transversal study

Cohort of patients between 18 and 50 years of age, presenting a chronic form of Chagas' disease (cardiopathy, mega-colon or mega-esofagus), and presenting non of the exclusion criteria.

Recruitment via the existing patients list of positive Chagas serology of:

  • the SELADIS center (Instituto de Servicios de Laboratorio de Diagnostico e Investigacion en Salud UMSA -UNIVERSIDAD MAYOR DE SAN ANDRES-)
  • Private surrounding hospitals, Hospital de Clinicas and Centro de Seguro Social Universitario de La Paz (UMSA)
  • Laboratorio de Inmunodiagnostico Instituto Boliviano de Biologia de la Altura -IBBA-Dr Lourdes Echalar.

Informed consent signed.

1 to 3 consultations on a period of one to 2 weeks no follow-up (transversal study)

Invasive descriptive explorations (blood sample and urodynamic study, imposing the assent of the Comité Nacional de Bioética).

Main objective : Describe the prevalence of the lower urinary tract dysfunction in patients suffering from a chronic form of Chagas' disease. The main criteria evaluated is the sum of two symptom questionnaires IPSS and ICIQ (spanish official validated translation), focusing on urinary incontinence, voiding dysfunction and quality of life.

Secondary objectives :

All the included patients will be proposed an initial consult :

  • Anonymization of all the observation/results
  • Past history (pathology, actual treatment,...), search of the exclusion criteria, Chagas' disease symptomatology and treatment, urological symptomatology.
  • Validated questionnaires to evaluate urological symptoms, urinary incontinence, voiding dysfunction or acute urinary dysfunction, bladder hyperactivity, sexuality and fertility.
  • Clinical examination
  • Micturition calendar /48hours.
  • Uroflowmetry, followed by ultrasonography for post-void residual and upper-urinary tract dilatation.
  • Blood sample to evaluate renal function (plasmatic creatinina for CDK EPI formula). This blood sample can also be used to confirm the positive Chagas' serology if no serology is available (indirect immunofluorescence and ELISA).

Te participants presenting a symptomatic lower urinary tract dysfunction on the previous exams will be proposed a complete urodynamic exploration (cystomanometry, urethral profile, pression/flow study during mycturition).

Sterility of urine assessed before exam. Tecnical material imported from Spain, Albyn medical Smardyn and consummables. Electronic curves obtained from Phoenix software (Albyn).

Objective inclusion of 200 participants during 5 months, between June and October 2017, in the SELADIS Institute in La Paz, Bolivia. Director of study Dr Simone Frédérique Brenière (french), Bolivian Director of Institute Dra Susana Revollo.

02

Conditions studied

  • Chagas' Disease (Chronic) With Other Organ Involvement

Browse trials for

Keywords

  • chronic Chagas disease
  • bladder
  • lower urinary tract
  • urodynamic
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients presenting a chronic form of chagas disease diagnosed by the SELADIS institute (serology), by cardiology, gastro-enterology or infectious disease consultation in La Paz may be include, after the informed consent have been signed.

Inclusion criteria

  • Male or female between 18 and 50 years of age
  • Presenting a chronic form of Chagas disease : cardiopathy or enteropathy
  • Previously treated or not treated
  • Signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Diabetes
  • Neurologic pathology
  • Past history of extensive pelvic surgery
  • Vaginal prolaps > grade 3 of Baden \& Walker (female)
  • Past history of vertebral fracture > L2
04

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
152 participants (actual)
Patient registry
No

Groups and cohorts

  • Single cohort

    single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure.

    Diagnostic Test: Chagas serology · Biological: Creatinina · Procedure: Urodynamic exploration

Interventions

  • Diagnostic testChagas serology

    IFI + ELISA method if no biological confirmation of chagas disease is in our possession

  • BiologicalCreatinina

    Plasmatic single mesure after consultation 1, to evaluate renal function

  • ProcedureUrodynamic exploration

    With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled

05

What researchers measure

Primary outcomes

  1. Symptomatic patients

    ICIQ SF\>0 IPSS\>7 or past acute urinary retention IIEF5\<11

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

Secondary outcomes

  1. Megabladder

    Bladder capacity \>600cc and \<4 daily micturition

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

  2. Mega ureter

    Ultrasonographic dilatation of renal pelvis\>20mm or of ureter \>7mm

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

  3. Hyperactive bladder

    \>8 daily micturition + urgency on dairy subsection detrusor hyperactivity on cystomanometry

    Time frame: micturition calendar over 2 days (transversal study, the participant will not be followed)

  4. Detrusor underactivity

    Qmax\<15 mL/s and post void residual\>150cc per-micturition pressure \<40 cm H2O

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

  5. Renal insufficiency

    CDK EPI\<60 mL/mn

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

  6. Urinary recurrent infections

    past history \> 3 pyélonephritis or \>5 cystitis/year in the past 5 years, if associated with dilatated ureter/renal pelvis or significant post void residual

    Time frame: reported infections duing the last 5 years (transversal study, the participant will not be followed)

  7. Urinary sphincter insufficiency

    P max\<30 cm H20 and stress urinary incontinence

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

  8. Erectile dysfunction in males

    IIEF5 \<16

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

  9. Hypofertility

    oral assess by difficulty to obtain pregnancy \>1 year

    Time frame: at consultation : 1 day (transversal study, the participant will not be followed)

06

Study locations

1 site
  • SELADIS Institute, Universidad Mayor de San Andrès
    La Paz, Bolivia
07

References and documents

Related links

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03189056
Lead sponsor
Institut de Recherche pour le Developpement
Collaborators
Instituto de Investigación Hospital Universitario La Paz
Responsible party
Elsa BEY (Resident in urological surgery, Institut de Recherche pour le Developpement) — Principal investigator
First posted
Jun 16, 2017
Start date
Jul 14, 2017
Primary completion
Oct 20, 2017
Completion
Oct 20, 2017
Last update
Mar 29, 2018

Study contacts

Elsa BEY, Resident
principal investigator · IRD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion